HUP0400645A2 - NMDA-receptor agonistát tartalmazó gyógyászati készítmények - Google Patents
NMDA-receptor agonistát tartalmazó gyógyászati készítményekInfo
- Publication number
- HUP0400645A2 HUP0400645A2 HU0400645A HUP0400645A HUP0400645A2 HU P0400645 A2 HUP0400645 A2 HU P0400645A2 HU 0400645 A HU0400645 A HU 0400645A HU P0400645 A HUP0400645 A HU P0400645A HU P0400645 A2 HUP0400645 A2 HU P0400645A2
- Authority
- HU
- Hungary
- Prior art keywords
- disease
- contain
- dementia
- preparations
- hydroxy4
- Prior art date
Links
- 239000003706 n methyl dextro aspartic acid receptor stimulating agent Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 abstract 3
- QEMSVZNTSXPFJA-HNAYVOBHSA-N 1-[(1s,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]-4-phenylpiperidin-4-ol Chemical compound C1([C@H](O)[C@H](C)N2CCC(O)(CC2)C=2C=CC=CC=2)=CC=C(O)C=C1 QEMSVZNTSXPFJA-HNAYVOBHSA-N 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 238000001356 surgical procedure Methods 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000013016 Hypoglycemia Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 abstract 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 206010046555 Urinary retention Diseases 0.000 abstract 1
- 201000004810 Vascular dementia Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 210000000748 cardiovascular system Anatomy 0.000 abstract 1
- 229910001431 copper ion Inorganic materials 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A találmány olyan, stabil gyógyászati készítményekre vonatkozik,amelyek hatóanyagként egy N-metil-D-aszparaginsav (NMDA) receptorantagonistát, azaz (1S,2S)-1-(4-hidroxifenil)-2(4-hidroxi4-fenilpiperidin-l-il)-1-propanolt tartalmaznak. A találmány szerintigyógyászati készítmények felhasználhatók sztrók, a gerincvelősérülései, traumás agysérülések, multiinfarktusos demencia, a központiidegrendszer degeneratív megbetegedései, így például Alzheimer-kór,Alzheimer-típusú öregkori demencia, Huntington-kór, Parkinson-kór,epilepszia, amiotrófiás egyoldali szklerózis, fájdalom, AIDSkövetkeztében fellépő demencia, pszichotikus állapotok, kábítószerhezvaló hozzászokás, migrén, hipoglükémia, azaz alacsony vércukorszint,szorongásos állapotok, vizelet-visszatartási nehézségek és a központiidegrendszerben végrehajtott sebészeti beavatkozás, úgynevezettnyitottszíves sebészeti beavatkozás vagy bármely olyan más eljáráskövetkeztében fellépő ischémiás esemény kezelésére, amelynek során akardiovaszkuláris rendszer funkciója sérülést szenved. A találmányszerinti készítményekre az jellemző, hogy farmakológiailag hatásosmennyiségben (1S,2S)-1-(4-hidroxifenil)-2-(4-hidroxi4-fenilpiperidin-l-il)-1-propanolt vagy ennek gyógyászatilag elfogadható sóját és vizettartalmaznak, mimellett az ilyen készítméryek kevesebb, mintkörülbelül 2 p.p.m. mennyiségű szabad réziont és kevesebb mintkörülbelül 2 p.p.m. szabad vasiont tartalmaznak. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25537200P | 2000-12-13 | 2000-12-13 | |
PCT/IB2001/002359 WO2002047685A2 (en) | 2000-12-13 | 2001-12-05 | Nmda receptor agonist pharmaceutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
HUP0400645A2 true HUP0400645A2 (hu) | 2004-06-28 |
Family
ID=22968017
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0400645A HUP0400645A2 (hu) | 2000-12-13 | 2001-12-05 | NMDA-receptor agonistát tartalmazó gyógyászati készítmények |
Country Status (42)
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2362560C2 (ru) | 2003-04-08 | 2009-07-27 | Проджиникс Фармасьютикалз, Инк. | Фармацевтическая препаративная форма |
TW200800959A (en) * | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
TW200811144A (en) * | 2006-06-09 | 2008-03-01 | Wyeth Corp | Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline |
TW200808741A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts |
TW200808740A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof |
TW200831096A (en) * | 2006-11-28 | 2008-08-01 | Wyeth Corp | Metabolites of 5-Fluoro-8-{4-[4-(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl} quinoline and methods of preparation and uses thereof |
TW200901974A (en) | 2007-01-16 | 2009-01-16 | Wyeth Corp | Compounds, compositions, and methods of making and using them |
CN101317844B (zh) * | 2007-06-08 | 2010-11-17 | 章劲夫 | 化合物(+)-5-甲基-10,11-二氢-5H-二苯并〔a,d〕环庚烯-5,10-亚胺在制备避孕药物中的应用 |
MX2011003015A (es) | 2008-09-18 | 2011-11-18 | Univ Northwestern | Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos. |
US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
US9101612B2 (en) | 2010-02-11 | 2015-08-11 | Northwestern University | Secondary structure stabilized NMDA receptor modulators and uses thereof |
KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | 2차 구조 안정화된 nmda 수용체 조절제 및 그의 용도 |
CN102586243A (zh) * | 2012-03-08 | 2012-07-18 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 一种预防电磁辐射致脑损伤的标志物 |
JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
WO2014120800A1 (en) | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
LT3514158T (lt) | 2013-01-29 | 2023-02-10 | Aptinyx Inc. | Spirolaktaminiai nmda receptoriaus moduliatoriai ir jų panaudojimas |
EA032153B1 (ru) | 2013-01-29 | 2019-04-30 | Аптиникс Инк. | Спиролактамные модуляторы nmda-рецептора и их применение |
BR112015018092A2 (pt) | 2013-01-29 | 2017-07-18 | Naurex Inc | moduladores de receptor de nmda de espiro-lactama e usos dos mesmos |
EA201591404A1 (ru) | 2013-01-29 | 2016-01-29 | Аптиникс Инк. | Спиролактамные модуляторы рецептора nmda и их применение |
WO2015099381A1 (ko) * | 2013-12-23 | 2015-07-02 | 주식회사 삼양바이오팜 | 팔로노세트론을 함유하는 약학 조성물 |
MX2018014202A (es) | 2016-05-19 | 2019-06-20 | Aptinyx Inc | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos. |
WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
AU2017305240B2 (en) | 2016-08-01 | 2021-12-09 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
AU2017306152A1 (en) | 2016-08-01 | 2019-01-31 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
MX2019001322A (es) | 2016-08-01 | 2019-09-11 | Aptinyx Inc | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos. |
BR112019001923A2 (pt) | 2016-08-01 | 2019-05-14 | Aptinyx Inc. | moduladores de nmda de espiro-lactama e métodos de sua utilização |
PE20190500A1 (es) | 2016-08-01 | 2019-04-10 | Aptinyx Inc | Moduladores del receptor nmda spiro-lactam y uso de los mismos |
JP7210599B2 (ja) | 2018-01-31 | 2023-01-23 | アプティニックス インコーポレイテッド | スピロラクタム系nmda受容体修飾因子およびその使用 |
US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5272160A (en) | 1989-05-17 | 1993-12-21 | Pfizer Inc | 2-piperidino-1-alkanol derivatives as antiischemic agents |
US5710168A (en) | 1991-10-23 | 1998-01-20 | Pfizer Inc. | 2-piperidino-1-alkanol derivatives as neuroprotective agents |
UA59341C2 (uk) * | 1995-08-11 | 2003-09-15 | Пфайзер, Інк. | (1s,2s)-1-(4-гідроксифеніл)-2-(4-гідрокси-4-фенілпіперидин-1-іл)-1-пропанолметансульфонат тригідрат |
TW450807B (en) * | 1995-09-15 | 2001-08-21 | Pfizer | Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents |
-
2001
- 2001-05-12 UA UA2003065485A patent/UA73619C2/uk unknown
- 2001-12-05 DE DE60111265T patent/DE60111265T2/de not_active Expired - Fee Related
- 2001-12-05 MX MXPA03005257A patent/MXPA03005257A/es active IP Right Grant
- 2001-12-05 EP EP01270205A patent/EP1347760B1/en not_active Expired - Lifetime
- 2001-12-05 AU AU2002218454A patent/AU2002218454B2/en not_active Ceased
- 2001-12-05 DZ DZ013484A patent/DZ3484A1/fr active
- 2001-12-05 US US10/010,827 patent/US6635270B2/en not_active Expired - Fee Related
- 2001-12-05 EA EA200300514A patent/EA006489B1/ru not_active IP Right Cessation
- 2001-12-05 CA CA002431172A patent/CA2431172A1/en not_active Abandoned
- 2001-12-05 IL IL15581001A patent/IL155810A0/xx unknown
- 2001-12-05 ES ES01270205T patent/ES2239648T3/es not_active Expired - Lifetime
- 2001-12-05 WO PCT/IB2001/002359 patent/WO2002047685A2/en not_active Application Discontinuation
- 2001-12-05 AT AT01270205T patent/ATE296629T1/de not_active IP Right Cessation
- 2001-12-05 YU YU41103A patent/YU41103A/sh unknown
- 2001-12-05 OA OA1200300145A patent/OA12414A/en unknown
- 2001-12-05 NZ NZ525742A patent/NZ525742A/en unknown
- 2001-12-05 KR KR10-2003-7007874A patent/KR100533407B1/ko not_active IP Right Cessation
- 2001-12-05 CN CNB018203922A patent/CN1273135C/zh not_active Expired - Fee Related
- 2001-12-05 PT PT01270205T patent/PT1347760E/pt unknown
- 2001-12-05 AU AU1845402A patent/AU1845402A/xx active Pending
- 2001-12-05 EE EEP200300284A patent/EE200300284A/xx unknown
- 2001-12-05 GE GE5171A patent/GEP20053568B/en unknown
- 2001-12-05 CZ CZ20031543A patent/CZ20031543A3/cs unknown
- 2001-12-05 HU HU0400645A patent/HUP0400645A2/hu unknown
- 2001-12-05 BR BR0116085-0A patent/BR0116085A/pt not_active IP Right Cessation
- 2001-12-05 JP JP2002549256A patent/JP2004515529A/ja active Pending
- 2001-12-05 PL PL01362080A patent/PL362080A1/xx not_active Application Discontinuation
- 2001-12-05 SK SK698-2003A patent/SK6982003A3/sk unknown
- 2001-12-10 DO DO2001000300A patent/DOP2001000300A/es unknown
- 2001-12-11 PE PE2001001235A patent/PE20020710A1/es not_active Application Discontinuation
- 2001-12-11 AR ARP010105748A patent/AR035607A1/es unknown
- 2001-12-12 TN TNTNSN01173A patent/TNSN01173A1/fr unknown
- 2001-12-12 UY UY27068A patent/UY27068A1/es not_active Application Discontinuation
- 2001-12-13 PA PA20018534901A patent/PA8534901A1/es unknown
- 2001-12-13 AP APAP/P/2001/002376A patent/AP1235A/en active
-
2003
- 2003-05-08 IS IS6811A patent/IS6811A/is unknown
- 2003-05-09 BG BG107788A patent/BG107788A/bg unknown
- 2003-05-20 ZA ZA200303892A patent/ZA200303892B/en unknown
- 2003-06-03 MA MA27191A patent/MA26970A1/fr unknown
- 2003-06-11 HR HR20030473A patent/HRP20030473A2/hr not_active Application Discontinuation
- 2003-06-12 NO NO20032678A patent/NO20032678L/no not_active Application Discontinuation
- 2003-06-13 EC EC2003004655A patent/ECSP034655A/es unknown
- 2003-08-19 US US10/643,441 patent/US20040039022A1/en not_active Abandoned
-
2004
- 2004-04-07 HK HK04102474A patent/HK1059575A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0400645A2 (hu) | NMDA-receptor agonistát tartalmazó gyógyászati készítmények | |
ES2284740T3 (es) | Carboxilato de terfenadina y el tratamiento de la irritacion cutanea. | |
CA2545503C (en) | Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases | |
WO2002042462A3 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
CA2433585A1 (en) | Pharmaceutical compositions containing donepezil hydrochloride | |
BG106251A (en) | Levodopa (carbidopa) entacapone pharmaceutical preparation | |
MXPA04005444A (es) | Ureas de 2-aminobenzotiazoles como moduladores de adenosina. | |
HK1049448A1 (en) | Improved transdermal therapeutic system for the treatment of parkinson's disease | |
UA92181C2 (ru) | Производные пиримидина и их применение в терапии и в производстве лекарственного средства для предотвращения и/или лечения болезни альцгеймера | |
EA200970148A1 (ru) | Фармацевтический состав, содержащий донепезил | |
BR9916361A (pt) | Forma de dosagem de tabletes de liberação controlada, formulação de tablete de liberação controlada, composição granular para prensagem em uma forma de dosagem de tablete de liberação controlada, e, métodos para preparar uma composição granular, para preparar uma forma de dosagem de tabletes de liberação controlada de divalproex sódio e para tratar epilepsia | |
TW200944198A (en) | Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use | |
KR20170083509A (ko) | 바레니클린 또는 이의 약학적으로 허용가능한 염을 함유하는 맛 차폐된 구강 투여용 약학 제제 | |
TW201116273A (en) | Co-crystals of tramadol and coxibs | |
HK1087039A1 (en) | Use of biphosphonate in preparing medical kit and a kit used for increasing bone mass | |
CN105792821A (zh) | 包含1-茚满硫酰胺衍生物的疼痛治疗剂和/或预防剂 | |
KR100259567B1 (ko) | 신경변성 질환 치료용 1-페닐-2-(2-피리디닐)에틸아민 에난티오머 | |
JP2004524357A5 (hu) | ||
TWI290831B (en) | Agent for treating Parkinson's disease comprising astrocyte function-improving agent as active ingredient | |
AP2001002119A0 (en) | Sertraline oral concentrate. | |
Maclennan et al. | Ginkgolide B accelerates vestibular compensation of spontaneous ocular nystagmus in guinea pig following unilateral labyrinthectomy | |
WO2008057599A3 (en) | Methods for the treatment of abeta related disorders and compositions therefor | |
CN109966278B (zh) | 草酰苹果酸在制备治疗神经细胞损伤的药物中的应用 | |
MY131159A (en) | New pharmaceutical compositions containing epinastine and pseudoephedrine | |
JPH0840902A (ja) | 末梢神経障害および中枢神経変性疾患の治療に有用な医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |